Treating Parkinson disease using umbilical cord blood mesenchymal stem cell

Journal of Clinical Rehabilitative Tissue Engineering Research October 1, 2009 Vol.13, No.40

Wu Li-ke, Wang Xiao-juan, Chu Sai-chun, Xu Bao-lei, Cheng Bo

Wu Stem Cells Medical Center, Beijing 100070 China

Abstract

OBJECTIVE: To observe the curative effect of umbilical cord blood mesenchymal stem cells (MSCs) implantation in treating Parkinson Disease.

METHODS: A total of 30 Parkinson patients in Beijing Wu Stem Cells Medical Center, from January to December 2008, were selected, including 19 males and 11 females, aged 45-66 years, mean aged 58 years,2-4 grade according to Hoehn-Yahr classification. The informed consent was obtained from each patient, and the treating was approved by the Medical Ethics Committee. The routine examination showed all patients were at normal level at blood, urine, stool test, liver/renal function, as well as tumor markers at first week. From the second week, all patients received MSCs implantation by lumbar puncture via subarachnoid space, the 3, 4 lumbar was served as puncture points. Totally 5 mL (5 000 000 cells) MSCs were slowly injected within 10 minutes, once per week, for 4 successive weeks. Unified Parkinson's Disease Rating Scale (UPDRS) was used to evaluate those Parkinson patients' neural function, the greater scores, the severe damage.

RESULTS: All patients were included in the final analysis without loss. Compared to before transplantation, the UPDRS was significant decreased at 3 month after treatment (P < 0.01). The clinical symptoms, such as tremor, rigidity, slow movement, unstable posture had obvious improvement, in addition, there was no graft versus host disease occurred.

CONCLUSION: MSCs implantation can ameliorate clinical symptoms, as well as improve life quality of Parkinson patients in some extent.